|
4DMT announced a license agreement with Astellas to utilize 4DMT’s proprietary intravitreal retinotropic R100 vector for genetic targets implicated in rare monogenic ophthalmic diseases. 4DMT received $20 million upfront, and may receive potential future option fees and milestones of up to $942.5 million including potential near-term development milestones.
Caribou Biosciences announced a $25 Million Equity Investment from Pfizer and closed upsized public offering delivering $134.6 million in net proceeds.
Carmot Therapeutics raised $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes.
Catalent Pharma announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.
Climax Foods appeared in a San Francisco Chronicle feature article on September 14 noting that Climax has unlocked the secret to vegan cheese that actually melts.
Eureka Therapeutics was awarded a $10.6 Million CIRM Grant to support clinical trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer.
Gritstone Bio announced an agreement with Genevant Sciences for have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccine. Gritstone also announced a partnership with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project.
Joint BioEnergy Institute collaborated with researchers at two other Berkeley Lab facilities (the Molecular Foundry and the Advanced Light Source) to successfully engineer microbes to make biological alternatives for the starting ingredients in an infinitely recyclable plastic known as poly(diketoenamine), or PDK.
Kyverna Therapeutics announced a collaboration with Verily to advance cell therapy for autoimmune diseases and the close of a Series B financing round to $145m while brining in new investors plus the achievement of 28day post-infusion milestone for first U.S. patient dosed in Phase 1 clinical trial of CD19 CAR T-Cell Therapy for Lupus Nephritis.
Pivot Bio blazed past $100m revenue mark and announced that co-founder Karsten Temme will become the company’s chief innovation officer, passing the CEO role to agtech industry veteran and Pivot Bio board member Chris Abbott.
a feature story in Berkeleyside noted that the Squishy Robotics device "looks like a toy, but acts like an action hero."
Upside Foods makes history with first cultivated meat sale in the U.S. and media coverage in the Washington Post, CBS Sunday News, and other outlets.
.
| 
